Recently, Foresite Capital posited that they had added Molly He as a venture partner. Dr. Molly joins the healthcare growth equity firm from Illumina where she worked as a senior director in charge of scientific research. Dr. Molly will enhance Foresite Capital’s operations considering that she has more than 15 years of experience in genomic and pharmaceutical research and development.
According to Jim Tananbaum, Dr. Molly He is one of the highly respected scientific researchers in the next generation sequencing. He reiterated that they would be happy to work with her. Tananbaum is the CEO and managing director of Foresite Capital. He also added that she will be an invaluable resource to the company due to her remarkable record in leadership and expertise in genomics, and drug development. Her contribution will be integral to the firm, as it continues to grow and diversify its portfolio.
At Illumina, Molly He was responsible for enhancing its protein reagent objectives. Previously, Dr. He worked for Pacific Biosciences as the head of protein sciences. She played a significant role in enhancing the company’s protein reagent development for Pacific Biosciences’ single molecular real-time sequencing chemistry.
According to INC42, at the start of her career, Dr. Molly He spent 10 years working in the pharmaceutical industry. She specialized in the structural-based design of antibody along with small molecule drugs that targeted cancer and immune diseases. She has a bachelor’s degree in biochemistry from Nankai University. Additionally, she holds a PhD in protein biophysics from the celebrated University of California. Molly has written more than 20 papers. In addition, she is a holder of more than 20 patent applications and issued patents. Her patents focus on the next-generation sequencing and personalized medicine. She said that she was pleased to join Foresite Capital, a company that is reputable for investing in the most innovative firms in the healthcare industry.
About Jim Tananbaum
Jim Tananbaum earned his M.D from Harvard Medical School. He also holds an MBA from the revered Harvard Business School. Moreover, Jim has a B.S.E.E and B.S from Yale University. The executive is credited for providing transformative leadership at Foresite Capital Management.
Over the years, Jim has invested in 21 healthcare firms, including Amira Pharmaceuticals and Amerigroup. Previously, Jim established Theravance and GelTex Pharmaceuticals, where he also served in various management positions. He is the recipient of various awards. Recently, Forbes honored him by including his name in the Midas List of Top Tech Investors. More details can be found on Researchgate.
Check out: https://www.facebook.com/foresitecapital